Closures a sign of Novartis minimizing production in Switzerland

The recently announced site closures by Novartis ($NVS) in Switzerland may be an indication that the country's pharmaceutical industry is being forced to move away from mass production. "High quality products that require a lot of research and development will always be made in Switzerland while finished products will be made elsewhere," said Julius Bär economist Janwillem Acket in Le Temps. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.